What is Plant Bioscience?
Plant Bioscience is dedicated to revolutionizing the treatment of serious infections through the development of innovative oligonucleotide-based antimicrobials. The company's core mission is to improve patient well-being and combat the escalating threat of antimicrobial resistance (AMR). Their research focuses on creating novel medicines effective against resistant bacterial strains, employing a strategic approach to drug discovery and development within the biotech sector. The company's commitment to addressing AMR positions it as a key player in a critical global healthcare challenge.
How much funding has Plant Bioscience raised?
Plant Bioscience has raised a total of $1.2M across 1 funding round:
Other Financing Round
$1.2M
Other Financing Round (2019): $1.2M with participation from REPAIR Impact Fund
Key Investors in Plant Bioscience
REPAIR Impact Fund
The REPAIR Impact Fund, backed by Novo Holdings, is dedicated to replenishing the anti-infective pipeline to combat antimicrobial resistance. It strategically invests in companies focused on the discovery and early-stage development of therapies targeting resistant microorganisms, addressing a critical global health issue.
What's next for Plant Bioscience?
With a major enterprise-level funding context and a recent strategic investment, Plant Bioscience is poised for accelerated growth and pipeline expansion. The company's focus on combating antimicrobial resistance aligns with significant global health priorities, suggesting potential for further strategic partnerships and substantial follow-on financing. Future endeavors will likely concentrate on advancing their oligonucleotide-based antimicrobials through clinical trials and scaling manufacturing capabilities to meet the growing demand for effective AMR solutions. This strategic backing provides a robust foundation for achieving their ambitious goals.
See full Plant Bioscience company page
